TY  - GEN
AU  - Mazières,J
AU  - Barlesi,F
AU  - Filleron,T
AU  - Besse,B
AU  - Monnet,I
AU  - Beau-Faller,M
AU  - Peters,S
AU  - Dansin,E
AU  - Früh,M
AU  - Pless,M
AU  - Rosell,R
AU  - Wislez,M
AU  - Fournel,P
AU  - Westeel,V
AU  - Cappuzzo,F
AU  - Cortot,A
AU  - Moro-Sibilot,D
AU  - Milia,J
AU  - Gautschi,O
TI  - Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
SN  - 1569-8041
PY  - 2016///1111
KW  - Adenocarcinoma
KW  - drug therapy
KW  - Adenocarcinoma of Lung
KW  - Adult
KW  - Afatinib
KW  - Aged
KW  - Aged, 80 and over
KW  - Anaplastic Lymphoma Kinase
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cohort Studies
KW  - Disease-Free Survival
KW  - ErbB Receptors
KW  - genetics
KW  - Europe
KW  - Female
KW  - Humans
KW  - Lapatinib
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Molecular Targeted Therapy
KW  - methods
KW  - Quinazolines
KW  - Quinolines
KW  - Receptor Protein-Tyrosine Kinases
KW  - Receptor, ErbB-2
KW  - Retrospective Studies
KW  - Trastuzumab
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdv573
ER  -